Advances in nano-delivery systems targeting hepatic stellate cells for hepatic fibrosis
JIN Wenzhen1 TAN Xiaochuan1 WEN Jin2 SONG Hui1 ZHANG Yujia1 ZHENG Wensheng1
1.Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing City Key Laboratory of Drug Delivery Technology and Novel Formulation, Beijing 100050, China;
2.Chinese Pharmaceutical Association, Beijing 100022, China
Abstract：Hepatic fibrosis, a chronic disease, proposes a serious threat to human health. The low efficiency and occurrence of side effects are often contributed by the lack of liver specificity. In order to improve the therapeutic effect of liver fibrosis，research about the use of nanocarriers to achieve targeted delivery has become more and more extensive. This review summarizes the nano-delivery carriers targeting hepatic stellate cells that have been applied in the treatment of liver fibrosis in recent years from the type of carriers and target receptors，which offer a new idea to treat liver fibrosis and serve as the basis of designing safe and effective drug delivery systems for liber fibrosis.
[1] Iwaisako K，Jiang C，Zhang M，et al. Origin of myofibroblasts in the fibrotic liver in mice [J]. Proc Natl Acad Sci USA，2014，111（32）：3297-3305.
[2] Blouin A，Bolender RP，Weibel ER. Distribution of organelles and membranes between hepatocytes and nonhepatocytes in the rat liver parenchyma. A stereological study [J]. J Cell Biol，2013，72（2）：441-455.
[3] Kisseleva T，Brenner DA. Hepatic stellate cells and the reversal of fibrosis [J]. J Gastroenterol Hepatol，2010，21（s3）：S84-S87.
[4] Xu T，Ni MM，XingLi，et al. NLRC5 regulates TGF-β1-induced proliferation and activation of hepatic stellate cells during hepatic fibrosis [J]. Int J Biochem Cell Biol，2016，70：92-104，447-457.
[5] Hernandezgea V，Friedman SL. Pathogenesis of Liver Fibrosis [J]. Annu Rev Pathol，2011，6（1）：425-456.
[6] York SJ，Arneson LS，Gregory WT，et al. The rate of internalization of the mannose 6-phosphate/insulin-like growth factor Ⅱ receptor is enhanced by multivalent ligand binding [J]. J Biol Chem，1999，274（2）：1164-1171.
[7] Hagens WI，Olinga P，Meijer DKF，et al. Gliotoxin non-selectively induces apoptosis in fibrotic and normal livers [J]. Liver Int，2010，26（2）：232-239.
[8] Adrian JE，Kamps JAAM，Scherphof GL，et al. A novel lipid-based drug carrier targeted to the non-parenchymal cells， including hepatic stellate cells，in the fibrotic livers of bile duct ligated rats [J]. Biochim Biophys Acta，2007，1768（6）：1430-1439.
[9] Luk JM，Zhang QS，Lee NP，et al. Hepatic stellate cell-targeted delivery of M6P-HSA-glycyrrhetinic acid attenuates hepatic fibrogenesis in a bile duct ligation rat model [J]. Liver Int，2010，27（4）：548-557.
[10] Zingarelli B，Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation [J]. Shock，2005，23（5）：393-399.
[11] Adrian JE，Kamps JA，Poelstra K，et al. Delivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomes [J]. J Drug Target，2007，15（1）：75-82.
[12] Kumar V，Mondal G，Dutta R，et al. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis [J]. Biomaterials，2016，76：144-156.
[13] Beljaars L，Olinga P，Molema G，et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6-phosphate modified albumin [M6P（28）-HSA] [J]. Liver Int，2010，21（5）：320-328.
[14] Cao Q，Han X，Li L. Enhancement of the efficiency of magnetic targeting for drug delivery： Development and evaluation of magnet system [J]. J Magn Magn Mater，2011， 323（15）：1919-1924.
[15] Chai NL，Fu Q，Shi H，et al. Oxymatrine liposome attenuates hepatic fibrosis via targeting hepatic stellate cells [J]. World J Gastroenterol，2012，18（31）：4199-4206.
[16] Du SL，Pan H，Lu WY，et al. Cyclic Arg-Gly-Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats [J]. J Pharmacol Exp Ther，2015，322（2）：560-568.
[17] Yang J，Hou Y，Ji G，et al. Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats [J]. Eur J Pharm Sci，2014， 52（1）：180-190.
[18] Blaner WS，Yang L，Brun PJ，et al. Vitamin A Absorption，Storage and Mobilization [J]. Subcell Biochem，2016， 81：95-125.
[19] Elmezayen NS，Elhadidy WF，Elrefaie WM，et al. Oral vitamin-A-coupled valsartan nanomedicine： High hepatic stellate cell receptors accessibility and prolonged enterohepatic residence [J]. J Control Release，2018，283：32-44.
[20] Elmezayen NS，Elhadidy WF，Elrefaie WM，et al. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib：A novel strategy with potent efficacy in experimental liver fibrosis [J]. J Control Release，2017，266：226-237.
[21] Narmada BC，Kang Y，Venkatraman L，et al. Hepatic Stellate Cell–Targeted Delivery of Hepatocyte Growth Factor Transgene via Bile Duct Infusion Enhances Its Expression at Fibrotic Foci to Regress Dimethylnitrosamine-Induced Liver Fibrosis [J]. Hum Gene Ther，2013，24（5）：508-519.
[22] Bansal R，Nagórniewicz B，Prakash J. Clinical Advancements in the Targeted Therapies against Liver Fibrosis [J]. Mediators Inflamm，2016，2016（3）：1-16.
[23] Qiao JB，Fan QQ，Xing L，et al. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis [J]. J Control Release，2018，283：113-125.
[24] Pinzani M，Gesualdo L，Sabbah GM，et al. Effects of platelet-derived growth factor and other polypeptide mitogens on DNA synthesis and growth of cultured rat liver fat-storing cells [J]. J Clin Invest，1989，84（6）：1786-1793.
[25] Li F，Li QH，Wang JY，et al. Effects of interferon-gamma liposomes targeted to platelet-derived growth factor receptor–beta on hepatic fibrosis in rats [J]. J Control Release，2012，159（2）：261-270.
[26] Higashi T，Friedman SL，Hoshida Y. Hepatic stellate cells as key target in liver fibrosis [J]. Adv Drug Deliv Rev，2017， 121：27-42.
2019, Vol. 16 
京公网安备 11010502046598号